Search results

This study aims to review the extant literature in pharmaceutical sector on corporate social responsibility (CSR), sustainability and organizational performance to explore if a relationship exists among these three elements.

A total of 301 research articles were collected from online databases. A new ECG framework representing environment, community and growth was used to classify the collected literature under the three elements: CSR, sustainability and organizational performance.

Key findings under the identified categories are: A) Environment: Strict legislation and green chemistry have revolutionized the pharmaceutical sector by decreasing manufacturing costs, minimizing the environmental footprint and improving compliance with regulations. B) Community: Community goodwill and organization’s image have gained importance under the influence of external and internal stakeholders. C) Growth: A weak relationship exists between CSR and organizational performance but increases engagement in sustainability practices which has led to increased market performance. Effective integration of social and environmental goals with strategic business processes could result in long-term profits.

This study focuses on the extant literature to identify the significance of CSR and sustainability on the organizational performance of the pharmaceutical sector. The propositions developed in this study will help in identifying the interdependency of the aforementioned three elements opening further possibilities of in-depth sector specific studies.

Using the pharmaceutical sector as a microcosm of the health sector, we highlight the most prevalent structural and policy issues that make this sector susceptible to corruption and ways in which these vulnerabilities can be addressed. We conducted a literature review of publications from 2004 to 2015 that included books, peer-reviewed literature, as well as gray literature such as working papers, reports published by international organizations and donor agencies, and newspaper articles discussing this topic. We found that vulnerabilities to corruption in the pharmaceutical sector occur due to a lack of good governance, accountability, transparency, and proper oversight in each of the decision points of the pharmaceutical supply chain. What works best to limit corruption is context specific and linked to the complexity of the sector. At a global level, tackling corruption involves hard and soft international laws and the creation of international standards and guidelines for national governments and the pharmaceutical industry. At a national level, including civil society in decision-making and monitoring is also often cited as a positive mechanism against corruption. Anticorruption measures tend to be specific to the particular “site” of the pharmaceutical system and include improving institutional checks and balances like stronger and better implemented regulations and better oversight and protection for “whistle blowers,” financial incentives to refrain from engaging in corrupt behavior, and increasing the use of technology in processes to minimize human discretion. This chapter was adapted from a discussion piece published by Transparency International UK entitled Corruption in the Pharmaceutical Sector: Diagnosing the Challenges.

This research aimed to investigate the information-seeking behaviour (ISB) and information needs of different professional groups within the pharmaceutical manufacturing sector in the Republic of Ireland (i.e. for what purpose information is acquired), the information sources professional groups use (including in-house documentation, regulations, industry guidelines, standards and colleagues) and the factors, which influence professional groups' choice of information sources. Furthermore, the research explored the perceived level of support that exists towards knowledge and information sharing.

A quantitative non-experimental research design, comprising of a self-completion survey questionnaire, was used to examine a number of information-seeking variables: information triggers, information sources and source influencers as well as information sharing enablers. It was related to four professional tasks: process technology/process development, regulatory support and quality/compliance support and engineering.

The research provides new insights into the ISB of pharmaceutical professionals working within a highly regulated and high-performance production environment, including a greater understanding of the context in which professional groups experience information needs. The levels of agreement observed in relation to employees' perception of information-sharing enablers indicated an overall positive level of information sharing.

The study points to largely echoed previous findings which suggest that individual work role associated tasks prompt particular information needs. Further to this, work role associated tasks have a bearing on information source selection. Pharmaceutical professionals engaged in positive levels of information and knowledge sharing, relying on procedures, other colleagues and internal documentation as information sources. The participants also indicated a high level of agreement in respect to the value of available subject matter experts as information-sharing enablers.

Organisations should aim to create opportunities for adequate time to share information and organisational structures, facilitating an overall organisational culture of sharing. A focus on information sharing through forums, seminars, meetings and working groups could enhance information sharing, through the development of communities of practice.

Pharmaceutical professionals relied on trustworthiness and quality as professional' top information source-influencing factors. Furthermore, the study demonstrated that working within a high-performance, target-driven and time-constrained production environment brings a particular contextual impact, where frequent urgent information triggers are experienced. These contextual factors warrant further investigation.

A paucity of information exists with respect to the ISB of professionals, working within the pharmaceutical manufacturing sector, which is a sector known for its high level of information use and production. This paper offered an original empirical investigation of the ISB of professionals, working within the pharmaceutical manufacturing sector in the Republic of Ireland, focussing on key professional tasks. The research also addressed the level of support available for knowledge and information sharing.

The purpose of this paper is twofold: first, it aims to investigate how internal and external drivers affect innovation in the Italian food industry. Second, the authors are interested to understand to what extent these drivers are industry specific, and therefore, they are contrasted against those relevant for the pharmaceutical industry in Italy according to the increasing growth of cross-industry innovation between these two sectors. The paper aims, thus, to shed light on the differences between food and pharmaceutical industries in terms of innovation drivers to understand potential precursors of emerging industry convergence.

Both probit and bivariate probit models are estimated, using data from the Italian Community Innovation Survey, in order to provide empirical evidence on drivers affecting innovation in the food and pharmaceutical industries.

The innovation activity of Italian food and pharmaceutical companies strongly relies on the presence of in-house R & D activities. Whereas firms in the pharmaceutical industry combine both internal and external R & D activities and knowledge sources to produce innovation, the case of the food industry is strongly dependent on the acquisition of external technology. In particular, the increased need for absorptive capacity of both sectors emphasises the key role of university research for collaboration, knowledge transfer and product innovation.

The paper gives insights not only on drivers for innovation, but especially on the industry-specific differences which should be taken into account to have a contingent view. Limitations concern the impossibility to perform panel data analysis, due to the design of the database. Furthermore, both food and pharmaceutical sub-samples are not completely representative, since large companies tend to be overrepresented.

This paper provides managerial insights concerning the internal and external drivers affecting innovation. Moreover, it raises awareness as regards the possible differences between the food and pharmaceutical industries, which is crucial for establishing successful pathways for cross-industry innovation.

This study represents one of the few attempts to compare the innovation drivers of two manufacturing sectors (food and pharmaceutical), increasingly involved in cross-industry collaborations, and to highlight the industry-specific differences in those drivers which can act as forerunners of this phenomenon.

This study aims to access, analyze and highlight opportunities and problems of the Indian pharmaceutical sector in the broader national health-care industry. The recent changes in the field, at the institutional and corporate levels, have placed India in the spotlight of the global pharmaceutical market, but several threats and weaknesses could limit this expansion.

Descriptive and inferential analyses have been based on empirical data extracted from authenticated data sources. Subsequently, a narrative strengths, weaknesses, opportunities and threats analysis was performed based on the results of prior investigations and on qualitative data that were retrieved from a marketing intelligence examination to generate an overall scenario analysis.

Indian pharmaceutical companies have faced several challenges on various fronts. In the home market, drug prices are controlled by the drug price control order; therefore, there is strong pressure on revenues and subsequently on costs. In the international market, threats derived from pharmaceutical multinational companies are emerging as tough obstacles to overcome.

More focus on patents for innovative drugs is required, instead of concentrating primarily on generic drugs. There is a need for policymakers to work on the sustainability and development of the industry, while the companies must redesign their orientation toward enhancing innovation capabilities. In addition, at the level of corporate strategy, firms should establish collaborations and alliances and expand their industrial marketing vision.

This study provides a global overview of the potential growth and development of the Indian pharmaceutical sector, comparing it with internal trends and external competition. The most relevant contribution of the research relies on the shift to innovative production that Indian companies must adopt (after years of focusing only on generic drugs), and in this vein, appropriate industrial marketing solutions are indispensable.

The current paper explores the effect of private market characteristics on the access of small and medium enterprises (SMEs) to public markets in some sectors. Using survey data of small and medium enterprises in the pharmaceutical sector in Egypt, we confirmed this effect. We found that regulations of drugs pricing and registration in the private market constrained the capacity of those firms to compete in the public markets. However, some other factors play it the other way. The policy implications of these findings indicate that governments need to account for private markets characteristics when designing support packages for smaller enterprises in public procurement markets.

Empirical studies on the supply chain quality management (SCQM) of the pharmaceutical sector are scarce and scattered. This paper investigates a set of key quality determinants in the pharmaceutical sector to offer a holistic quality control framework for its supply chain (SC).

A mixed-method design was used. A focused group discussion with seven pharmaceutical SC managers summarized the narratives of the SCQM in this sector and helped to develop a questionnaire. The survey data were collected from the managers of 299 pharmaceutical firms.

The statistical results show the key determinants are leadership (LS), customer focus (CF), process integration and management (PIM), supplier relations (SR), quality practice (QP), human resource practices (HRP) and safety (SF). Unlike many other sectors, in the pharmaceutical SC, logistics and inventory costs have been proved to be not as important as other measures in the eyes of the SC managers and as part of SCQM performance measures, which can be a result of the priority systems influenced by the World Health Organization standards.

The study is distinctive in its scope as is carried out in a developing country with focus on concept of SCQM with reference to pharmaceutical SC. It shows great potential for further studies and improvements in logistics and warehousing in this sector, for the interest of the pharmaceutical SC managers and regulators who aim to ensure safety and quality in the health-care sector.

This research investigates the effect of mergers and acquisition (M&A) transactions in the pharmaceutical sector. The study assesses the short-term value creation or destruction for shareholders of pharmaceutical companies involved in M&A activities on the acquiring side.

The empirical analysis is carried out by applying the event study methodology in order to define the cumulative abnormal return for each transaction observed. Then, the correlations between abnormal returns and economic metrics are determined building a multiple regression model. These metrics refers to the acquirer, target or to the deal itself.

Evidence show a short-term value creation for shareholders of pharmaceutical companies involved in M&A transactions on the acquiring side. On the one hand, the analysis suggests a negative correlation between the value creation and the acquiring firm's level of indebtedness. On the other hand, the value creation is positively correlated with target's metrics such as Return on Equity (ROE), Return on Assets (ROA) and Research and Development (R&D) intensity. Value creation is also tied to deal-specific characteristics regarding the cash used in the transaction and the comparative extent of the deal.

This analysis allows to predict returns around an announcement day considering the described indicators of value creation or destruction. M&As play a key role in the strategy implementation as reaction to exogenous shocks and endogenous needs.

This study enriches the literature of corporate finance applied to the pharmaceutical sector. Indeed, this industry is gaining increasing relevance in the M&A panorama. Thus, the related dynamics need to be assessed considering the uniqueness of the pharmaceutical sector in terms of regulation, stakeholders and social impact.

The imperative to conserve resources and minimize operational expenses has spurred a notable increase in the adoption of lean manufacturing within the context of the circular economy across diverse industries in recent years. However, a notable gap exists in the research landscape, particularly concerning the implementation of lean practices within the pharmaceutical industry to enhance circular economy performance. Addressing this void, this study endeavors to identify and prioritize the pivotal drivers influencing lean manufacturing within the pharmaceutical sector.

The outcome of this rigorous examination highlights that “Continuous Monitoring Process for Sustainable Lean Implementation,” “Management Involvement for Sustainable Implementation” and “Training and Education” emerge as the most consequential drivers. These factors are deemed crucial for augmenting circular economy performance, underscoring the significance of management engagement, training initiatives and a continuous monitoring process in fostering a closed-loop practice within the pharmaceutical industry.

The findings contribute valuable insights for decision-makers aiming to adopt lean practices within a circular economy framework. Specifically, by streamlining the process of developing a robust action plan tailored to the unique needs of the pharmaceutical sector, our study provides actionable guidance for enhancing overall sustainability in the manufacturing processes.

This study represents one of the initial efforts to systematically identify and assess the drivers to LM implementation within the pharmaceutical industry, contributing to the emerging body of knowledge in this area.

The purpose of this paper is to analyze the Chinese pharmaceutical sector through three levels: policy level, enterprise level, and technology level.

The authors explore the environmental impacts, which include political, social, and economic factors, study enterprise‐level strategies on international technology transfer and carry out a trend analysis on the technology development in the Chinese pharmaceutical industry.

The results indicate that China is emerging in the biopharmaceutical industry. While there are several steps to be taken at different levels, including policy, enterprise, and technology, the country is presenting a potential for the future. The paper outlines the gaps in each area.

The paper provides a very good outline against which any emerging economy could review its potential in the pharmaceutical industry.